NASA and SpaceX are targeting October 13 to launch the 35th commercial resupply mission to the International Space Station, carrying more than 6,300 pounds of supplies, hardware, and scientific experiments aboard a Dragon spacecraft on a Falcon 9 rocket from Cape Canaveral. The mission is routine logistics wrapped around a science payload that reveals where NASA thinks microgravity research is actually heading. The headline experiment is LambdaVision-1, which tests manufacturing artificial eye retinas in microgravity. The logic is straightforward: reduced settling in zero-g may produce more uniform, stable protein layers than ground-based fabrication allows. If it works, the implications extend beyond space — these implants target patients with currently incurable retinal diseases on Earth. This is NASA positioning the ISS not as a pure-science outpost but as a prototype manufacturing testbed. Three other investigations push in similar directions. Stellar Spheroids studies whether microgravity improves the formation of vascular networks in 3D human heart tissue models, with downstream applications in drug testing. ELF-Unconventional Glass 2 examines how glass made from non-traditional elements behaves when formed in space, targeting materials with higher strength and improved optical capabilities for spacecraft and habitats. MINDS sends brain organoids — "organoid villages" combining cells from multiple donors — to study neuroinflammation linked to Alzheimer's, Parkinson's, and multiple sclerosis. The cargo manifest also tells a hardware story. The final pair of International Space Station Roll-Out Solar Arrays (IROSAs) will complete the station's power augmentation, a project explicitly tied to supporting the station's eventual safe and controlled deorbit. A collapsible contingency urinal flies as a demonstration unit for Artemis III. And a large foam clamshell launches empty — its job is to return the failed Canadarm2 joint replaced during a June 30 spacewalk for ground analysis. NASA astronauts Anil Menon and Jessica Watkins will monitor Dragon's autonomous docking to the space-facing port of Harmony. The spacecraft will remain attached for roughly a month before splashing down in the Pacific in mid-November, returning the failed Canadarm2 joint, a spacesuit for refurbishment, and life-support components including a urine processor pump assembly and a water processor filtration unit. The broader context matters. The ISS has now supported research by scientists from more than 110 countries, enabling more than 4,000 experiments in microgravity over 25-plus years. But the station is approaching end-of-life, and these missions increasingly serve dual purposes: advancing science while also testing hardware and procedures for Artemis lunar missions and eventual Mars expeditions. Every toilet sensor, every solar array, every contingency urinal is doing double duty. CRS-35 is not a breakthrough mission. It is the kind of steady, incremental logistics run that keeps a $150 billion orbital laboratory functioning — and the science payload reveals NASA's thesis that microgravity manufacturing and biological research will eventually justify their cost outside of government funding.
